Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster - PhysicianPharm

Therapeutic activation of TiO2-Tf-TC nanoparticles by 89Zr-daratumumab in a multiple myeloma tumor model

ANCHAL GHAI, Alexander Zheleznyak, Dorota Grabowska, kvar black, julie prior, kiran vij, ravi vij, john dipersio, monica shokeen and samuel achilefu
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1300;
ANCHAL GHAI
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Zheleznyak
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Grabowska
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
kvar black
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
julie prior
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
kiran vij
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ravi vij
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
john dipersio
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
monica shokeen
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
samuel achilefu
1Washington University School of Medicine St Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1300

Background: Multiple myeloma (MM) is a debilitating hematological malignancy caused by abnormal plasma cells in the bone marrow. Despite recent advances in treatment strategies, MM patients frequently relapse and become refractory due to genetic instability and other microenvironmental factors. Photodynamic therapy (PDT) involves activating a photosensitizer by an external light source, leading to the production of reactive oxygen species (ROS), which mediates cell death by apoptosis. However, the limited tissue penetration of light hinders the treatment of deep seated tumors as most of the light is absorbed and/orscattered by the biological tissue. To overcome this limitation, an alternative approach is to use Cerenkov radiation, which is the UV and the visible light emitted during a radioactive decay by charged particles traveling through a dielectric medium at a speed greater than that of light. In this study, 89Zr-daratumumab, a CD38 targeted PET imaging agent, was employed as an in vivo depth-independent Cerenkov radiation source to excite titanium dioxide (TiO2) nanoparticles coated with transferrin (Tf) and titanocene (TC) (TiO2-Tf-TC) for generating ROS in a human MM mouse model.

Methods: TiO2-Tf-TC nanoparticles were synthesized in-house and characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS). Daratumumab was conjugated to DFO-Bz-NCS and radiolabeling of the conjugate was optimized with zirconium-89 (89Zr). Human MM cells, MM.1S, modified to express click beetle red luciferase (MM.1S-CBR) were injected in NSG mice subcutaneously and tumor progression was monitored by bioluminescence imaging (BLI). Cell viability assay was performed to evaluate the Cerenkov radiation-induced therapy (CRIT) response in vitro. 89Zr-daratumumab (1.11 MBq) was injected in mice via tail vein, followed by TiO2-Tf-TC nanoparticles at 3 d post-injection of the radiotracer. PET imaging with 89Zr-daratumumab and BLI was used to evaluate the therapeutic response of CRIT in vivo.

Results: TiO2 based nanoparticles were synthesized to target the Tf receptors (1:3 TiO2 to Tf mass ratio) by functionalizing the metal oxide surface with Tf, that enhanced dispersion and enabled the incorporation of TC. The nanoparticles’ size was confirmed by TEM and DLS to be 100nm and 105nm, respectively. Cells treated with 89Zr-daratumumab and TiO2-Tf-TC nanoparticles showed reduced viability of 52.8 ± 10.4% as compared to the untreated control (98.7 ± 1.5%), nanoparticles only (96.3 ± 0.4%), and 89Zr-daratumumab only (88 ± 0.4%) treatment groups. Compared to the 89Zr-daratumumab, TiO2-Tf-TC nanoparticles, and untreated controls, CRIT exhibited a significant decrease in the BLI signal of the MM.1S-CBR tumor in mice. The SUV of tumor in mice from the CRIT treatment group decreased from 2.85 to 1.90 post-therapy, whereas the SUV of the tumor increased from 2.58 to 3.02 in the mice injected with 89Zr-daratumumab only, showing inhibition of tumor progression by CRIT.

Conclusions: CRIT with a combination of 89Zr-daratumumab and TiO2-Tf-TC nanoparticles showed significant therapeutic effects on MM.1S-CBR cells in vitro and in vivo. The long half-life and high gamma energy of 89Zr are suitable for long-term tissue depth- and oxygen-independent photodynamic treatments. This study paves the way to use antibody labeled with positron emitters as an internal radiation source to activate the nanoparticle photosensitizers for the treatment of MM.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic activation of TiO2-Tf-TC nanoparticles by 89Zr-daratumumab in a multiple myeloma tumor model
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Therapeutic activation of TiO2-Tf-TC nanoparticles by 89Zr-daratumumab in a multiple myeloma tumor model
ANCHAL GHAI, Alexander Zheleznyak, Dorota Grabowska, kvar black, julie prior, kiran vij, ravi vij, john dipersio, monica shokeen, samuel achilefu
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1300;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Therapeutic activation of TiO2-Tf-TC nanoparticles by 89Zr-daratumumab in a multiple myeloma tumor model
ANCHAL GHAI, Alexander Zheleznyak, Dorota Grabowska, kvar black, julie prior, kiran vij, ravi vij, john dipersio, monica shokeen, samuel achilefu
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1300;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - PhysicianPharm

  • Preliminary result of Texture Analysis on prediction of overall outcome of neuroendocrine tumors based on pre-therapy heterogeneity of somatostatin receptors on 68Ga Dotatate PET/CT scans.
  • An empirical update of left ventricular 3D segmentation algorithm in myocardial perfusion SPECT imaging
  • Two-year change in 18F-sodium fluoride uptake in the aorta of healthy subjects and angina pectoris patients
Show more Poster - PhysicianPharm

Oncology (Science), Basic and Translation

  • Dynamic [18F]FSPG PET: impact of glutamate transport and glutaminase inhibition on redox imbalance and cell death in glutamine-dependent triple negative breast cancer
  • Suppression of tumor growth by combination therapy of photodynamic and bacteria in an orthotopic colon tumor model
  • Evaluation of the biodistribution of 18F-siPSMA-14 in the HET-CAM model
Show more Oncology (Science), Basic and Translation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire